Select the onboarding process you use to help
patients get started:
CoverMyMeds®
Complete prior authorization (PA) request via CoverMyMeds
(CMM) account 
NO PAPER. NO FAX. NO DUPLICATE SERVICES.
If PA approved
If PA denied
Prescription is transferred to the patient’s health plan–preferred specialty pharmacy for delivery.
All patients can conveniently enroll in COSENTYX® Connect, and eligible* privately insured patients can sign up for the Co-Pay offer† by visiting Connect.COSENTYX.com or by calling 1-844-COSENTYX (1-844-267-3689).
If the PA request was initiated by the specialty pharmacy, CMM will notify them of the approval so the pharmacy can schedule delivery with the patient.
To sign in or create an account, visit covermymeds.com
To sign in or create an account, visit covermymeds.com
Services provided by CoverMyMeds:
- Complete PA requests in minutes and get a response as quickly as in a few hours
- Electronic patient signatures
- Upon submission of the electronic Start Form, automatic hand-off to Covered Until You’re Covered Program‡ for eligible* privately insured patients and enrollment in COSENTYX® Connect
- CMM agents monitor case progress and alert the office if the patient’s health plan requests additional information
While coverage is being pursued, submit an electronic Start Form to COSENTYX® Connect via your CMM account to enroll patients in Covered Until You’re Covered.
Up to 2 years of FREE COSENTYX is available for eligible* privately insured patients during the appeals process.‡
See our Navigating SC Access Top Challenges resource for next steps to get patients started with Covered Until You’re Covered.
To sign in or create an account, visit covermymeds.com
To sign in or create an account, visit covermymeds.com
Services provided by CoverMyMeds:
- Complete PA requests in minutes and get a response as quickly as in a few hours
- Electronic patient signatures
- Upon submission of the electronic Start Form, automatic hand-off to Covered Until You’re Covered Program‡ for eligible* privately insured patients and enrollment in COSENTYX® Connect
- CMM agents monitor case progress and alert the office if the patient’s health plan requests additional information
Specialty Pharmacies
All specialty pharmacies can fill a
prescription for COSENTYX.
Pharmacists often coordinate the PA and appeals process, work
with the office to gain approval, and can transfer the
prescription to the patient’s health plan–preferred pharmacy, if required.
Send the COSENTYX prescription
directly to your preferred specialty
pharmacy.
If PA approved
If PA denied
Specialty pharmacy dispenses COSENTYX to the patient.
All patients can conveniently enroll in COSENTYX® Connect, and eligible* privately insured patients can sign up for the Co-Pay offer† by visiting Connect.COSENTYX.com or by calling 1-844-COSENTYX (1-844-267-3689).
Novartis does not recommend the use of any particular specialty pharmacy.
While coverage is being pursued, submit a Start Form to COSENTYX® Connect to enroll patients in Covered Until You’re Covered.
Up to 2 years of FREE COSENTYX is available for eligible* privately insured patients during the appeals process.‡
See our Navigating SC Access Top Challenges resource for next steps to get patients started with Covered Until You’re Covered.
Novartis does not recommend the use of any particular specialty pharmacy.
COSENTYX® Connect
Submit a completed Start Form to COSENTYX® Connect (patient must sign and date the Start Form).
Once the completed Start Form has been received, the COSENTYX® Connect team will conduct a benefits verification and provide support throughout the PA and appeals process.
If PA approved
If PA denied
Prescription is transferred to the patient’s health plan–preferred specialty pharmacy for delivery.
Eligible* privately insured patients will receive a call to collect information and explain the Co-Pay offer.† The co-pay card is emailed to the patient.
While coverage is being pursued, eligible* patients are auto-enrolled in Covered Until You’re Covered.
Up to 2 years of FREE COSENTYX is available for eligible* privately insured patients during the appeals process.‡
See our Navigating SC Access Top Challenges resource for next steps to get patients started with Covered Until You’re Covered.
COSENTYX® Connect is available to
patients across all 3 processes.
*Certain payers have carve-outs that restrict utilization of manufacturer support programs.
†Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.
‡The Covered Until You’re Covered Program is available for COSENTYX subcutaneous injection only. Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides COSENTYX for free to eligible patients for up to 2 years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after 2 years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.
CoverMyMeds is a registered trademark of CoverMyMeds LLC. All rights reserved.
FDA, US Food and Drug Administration; HIPAA, Health Insurance Portability and Accountability Act; ICD-10, International Classification of Diseases, Tenth Revision; PA, prior authorization.
3/24 304251
INDICATIONS
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
WARNINGS AND PRECAUTIONS
Infections
INDICATIONS
COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.
COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.
COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).
COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis and angioedema have been reported during treatment with COSENTYX.
WARNINGS AND PRECAUTIONS
Infections
COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe PsO, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed in subjects treated with COSENTYX compared to placebo-treated subjects. A similar increase in risk of infection in subjects treated with COSENTYX was seen in placebo‑controlled trials in subjects with PsA, AS and nr-axSpA. The incidence of some types of infections, including fungal infections, appeared to be dose‑dependent in clinical trials.
In the postmarketing setting, serious bacterial, viral, and fungal opportunistic infections, and some fatal infections have been reported in patients receiving IL-17 inhibitors including COSENTYX. Cases of Hepatitis B virus reactivation have been reported.
Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.
If signs of Hepatitis B virus reactivation occur, consult a hepatitis specialist. COSENTYX is not recommended for use in patients with active viral hepatitis.
Pre-treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.
Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) exacerbations, in some cases serious and/or leading to discontinuation of COSENTYX, occurred in COSENTYX treated subjects during clinical trials in PsO, PsA, AS, nr-axSpA, and HS. In adult subjects with HS, the incidence of IBD was higher in subjects who received COSENTYX 300 mg every 2 weeks (Ulcerative Colitis [UC] 1 case, EAIR 0.2/100 subject-years; Crohn’s Disease [CD] 1 case, EAIR 0.2/100 subject-years) compared to subjects who received COSENTYX 300 mg every 4 weeks (IBD 1 case, EAIR 0.2/100 subject-years). In addition, new onset IBD cases occurred in subjects treated with COSENTYX in clinical trials. In an exploratory trial in 59 subjects with active Crohn’s disease [COSENTYX is not approved for the treatment of Crohn’s disease], there were trends toward greater disease activity and increased adverse reactions in subjects treated with COSENTYX as compared to placebo-treated subjects.
Exercise caution when prescribing COSENTYX to patients with IBD. Patients treated with COSENTYX should be monitored for signs and symptoms of IBD.
Eczematous Eruptions
In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis‑like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.
Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.
Hypersensitivity Reactions
Serious hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported in COSENTYX treated subjects in clinical trials and in the post-marketing setting. If an anaphylactic or other serious allergic reaction occurs, immediately discontinue administration of COSENTYX and initiate appropriate therapy.
The removable caps of the COSENTYX Sensoready® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.
Immunizations
Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient’s immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.
MOST COMMON ADVERSE REACTIONS
Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.
Please see full Prescribing Information, including Medication Guide.